Market Intelligence chevron_right Medical Care chevron_right Biopharmaceutical and Bio-CDMO
Global Report 2025

Global Biopharmaceutical and Bio-CDMO Market Growth (Status and Outlook) 2024-2030

calendar_todayPublished: Mar 2025 descriptionPages: 121 categoryCategory: Medical Care
cloud_downloadRequest Sample Report
mailPre-Order Enquiry
local_offerGet Discount

The global Biopharmaceutical and Bio-CDMO market size is predicted to grow from US$ 27550 million in 2024 to US$ 59300 million in 2030; it is expected to grow at a CAGR of 13.6% from 2024 to 2030.

Biopharmaceutical Contract Development and Manufacturing Organizations (CDMOs) are companies that provide comprehensive services for the development and manufacturing of biopharmaceutical products. These organizations play a crucial role in the biopharmaceutical industry by offering a range of services to biotech and pharmaceutical companies, allowing them to outsource various stages of the drug development and manufacturing process.

  • Increasing Demand for Biologics: The rising demand for biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapies, is a significant driver. Biologics are increasingly becoming a focus for drug development due to their effectiveness in treating various diseases.
  • Cost-Effective Outsourcing: Outsourcing to CDMOs allows pharmaceutical and biotech companies to reduce capital expenditures, mitigate risks, and achieve cost savings. CDMOs offer specialized facilities and expertise, allowing clients to avoid the need for extensive in-house infrastructure.
  • Strategic Partnerships and Collaborations: Pharmaceutical and biotech companies increasingly engage in strategic partnerships with CDMOs to access specialized capabilities, share development risks, and benefit from the CDMO's expertise in specific technologies or therapeutic areas.

To meet the growing demand for biopharmaceuticals, CDMOs are investing in expanding their biomanufacturing capacities. This includes the construction of new facilities and the acquisition of advanced technologies to increase production capabilities.

The increasing interest and investment in cell and gene therapies have led to a rise in demand for CDMOs offering services in this area. Companies are seeking expertise in cell line development, viral vector production, and other specialized services related to advanced therapies.

Biopharmaceutical CDMOs are expanding their global presence to cater to the needs of a geographically diverse client base. This includes establishing facilities in key regions and forming strategic partnerships to enhance their global reach.

CDMOs are expanding their service offerings to provide integrated solutions covering the entire biopharmaceutical development and manufacturing lifecycle. This integrated approach aims to streamline processes and accelerate time to market for clients.

Segmentation by Type:

  • Cell and Gene Therapies
  • Antibodies
  • Vaccines
  • Other

Segmentation by Application:

  • SMBs
  • Large Companies

Market by Region:

  • Americas
  • APAC
  • Europe
  • Middle East & Africa

Company's Coverage:

  • Lonza
  • Catalent
  • Samsung Biologics
  • FUJIFILM Diosynth Biotechnologies
  • Boehringer Ingelheim
  • 药明生物
  • Recipharm
  • Thermo Fisher Scientific
  • AGC Biologics
  • Rentschler Biopharma
  • KBI Biopharma
  • Siegfried
  • Aenova Group
  • GenScript
  • ProBioGen
  • Northway Biotech
  • 3P Biopharmaceuticals

Key Questions Addressed in this Report:

Frequently Asked Questions

What is the USP of the report? expand_more
Biopharmaceutical and Bio-CDMO report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
What are the key content of the report? expand_more
Biopharmaceutical and Bio-CDMO report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
What are the value propositions and opportunities offered in this market research report? expand_more
Biopharmaceutical and Bio-CDMO report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.